世界の心臓代謝薬市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Cardiometabolic Drug Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z1127 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、98ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥546,000 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥819,000 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,092,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、心臓代謝薬のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（耐糖能障害薬、インスリン抵抗性薬、高血圧薬、脂質異常症薬、中枢性脂肪症薬）、用途別市場規模（病院薬局、オンライン薬局、小売薬局）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・心臓代謝薬の市場動向 ・企業の競争状況、市場シェア ・心臓代謝薬の種類別市場規模（耐糖能障害薬、インスリン抵抗性薬、高血圧薬、脂質異常症薬、中枢性脂肪症薬） ・心臓代謝薬の用途別市場規模（病院薬局、オンライン薬局、小売薬局） ・心臓代謝薬の北米市場規模2016-2027（アメリカ、カナダ） ・心臓代謝薬のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・心臓代謝薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・心臓代謝薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・心臓代謝薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Gilead Sciences、AbbVie、Sanofi、InovoBiologic、Carmel Biosciences、Genfit、Kochi Prefecture、Besins Healthcare） ・結論

Cardiometabolic drugs are purposefully used for a vast composition of metabolic dysfunction, disorders include impaired glucose tolerance, insulin resistance, hypertension, dyslipidemia, and central adiposity.

Market Analysis and Insights: Global Cardiometabolic Drug Market
The global Cardiometabolic Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Cardiometabolic Drug market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Cardiometabolic Drug market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Cardiometabolic Drug market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Cardiometabolic Drug market.

Global Cardiometabolic Drug Scope and Market Size
Cardiometabolic Drug market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Cardiometabolic Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Impaired Glucose Tolerance Drug
Insulin Resistance Drug
Hypertension Drug
Dyslipidemia Drug
Central Adiposity Drug

Segment by Application
Hospital Pharmacies
Online Pharnacies
Retail Pharmacies

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Gilead Sciences
AbbVie
Sanofi
InovoBiologic
Carmel Biosciences
Genfit
Kochi Prefecture
Besins Healthcare

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cardiometabolic Drug Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Impaired Glucose Tolerance Drug
1.2.3 Insulin Resistance Drug
1.2.4 Hypertension Drug
1.2.5 Dyslipidemia Drug
1.2.6 Central Adiposity Drug
1.3 Market by Application
1.3.1 Global Cardiometabolic Drug Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital Pharmacies
1.3.3 Online Pharnacies
1.3.4 Retail Pharmacies
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Cardiometabolic Drug Market Perspective (2016-2027)
2.2 Cardiometabolic Drug Growth Trends by Regions
2.2.1 Cardiometabolic Drug Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Cardiometabolic Drug Historic Market Share by Regions (2016-2021)
2.2.3 Cardiometabolic Drug Forecasted Market Size by Regions (2022-2027)
2.3 Cardiometabolic Drug Industry Dynamic
2.3.1 Cardiometabolic Drug Market Trends
2.3.2 Cardiometabolic Drug Market Drivers
2.3.3 Cardiometabolic Drug Market Challenges
2.3.4 Cardiometabolic Drug Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Cardiometabolic Drug Players by Revenue
3.1.1 Global Top Cardiometabolic Drug Players by Revenue (2016-2021)
3.1.2 Global Cardiometabolic Drug Revenue Market Share by Players (2016-2021)
3.2 Global Cardiometabolic Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Cardiometabolic Drug Revenue
3.4 Global Cardiometabolic Drug Market Concentration Ratio
3.4.1 Global Cardiometabolic Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cardiometabolic Drug Revenue in 2020
3.5 Cardiometabolic Drug Key Players Head office and Area Served
3.6 Key Players Cardiometabolic Drug Product Solution and Service
3.7 Date of Enter into Cardiometabolic Drug Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Cardiometabolic Drug Breakdown Data by Type
4.1 Global Cardiometabolic Drug Historic Market Size by Type (2016-2021)
4.2 Global Cardiometabolic Drug Forecasted Market Size by Type (2022-2027)

5 Cardiometabolic Drug Breakdown Data by Application
5.1 Global Cardiometabolic Drug Historic Market Size by Application (2016-2021)
5.2 Global Cardiometabolic Drug Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Cardiometabolic Drug Market Size (2016-2027)
6.2 North America Cardiometabolic Drug Market Size by Type
6.2.1 North America Cardiometabolic Drug Market Size by Type (2016-2021)
6.2.2 North America Cardiometabolic Drug Market Size by Type (2022-2027)
6.2.3 North America Cardiometabolic Drug Market Size by Type (2016-2027)
6.3 North America Cardiometabolic Drug Market Size by Application
6.3.1 North America Cardiometabolic Drug Market Size by Application (2016-2021)
6.3.2 North America Cardiometabolic Drug Market Size by Application (2022-2027)
6.3.3 North America Cardiometabolic Drug Market Size by Application (2016-2027)
6.4 North America Cardiometabolic Drug Market Size by Country
6.4.1 North America Cardiometabolic Drug Market Size by Country (2016-2021)
6.4.2 North America Cardiometabolic Drug Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Cardiometabolic Drug Market Size (2016-2027)
7.2 Europe Cardiometabolic Drug Market Size by Type
7.2.1 Europe Cardiometabolic Drug Market Size by Type (2016-2021)
7.2.2 Europe Cardiometabolic Drug Market Size by Type (2022-2027)
7.2.3 Europe Cardiometabolic Drug Market Size by Type (2016-2027)
7.3 Europe Cardiometabolic Drug Market Size by Application
7.3.1 Europe Cardiometabolic Drug Market Size by Application (2016-2021)
7.3.2 Europe Cardiometabolic Drug Market Size by Application (2022-2027)
7.3.3 Europe Cardiometabolic Drug Market Size by Application (2016-2027)
7.4 Europe Cardiometabolic Drug Market Size by Country
7.4.1 Europe Cardiometabolic Drug Market Size by Country (2016-2021)
7.4.2 Europe Cardiometabolic Drug Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Cardiometabolic Drug Market Size (2016-2027)
8.2 Asia-Pacific Cardiometabolic Drug Market Size by Type
8.2.1 Asia-Pacific Cardiometabolic Drug Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Cardiometabolic Drug Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Cardiometabolic Drug Market Size by Type (2016-2027)
8.3 Asia-Pacific Cardiometabolic Drug Market Size by Application
8.3.1 Asia-Pacific Cardiometabolic Drug Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Cardiometabolic Drug Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Cardiometabolic Drug Market Size by Application (2016-2027)
8.4 Asia-Pacific Cardiometabolic Drug Market Size by Region
8.4.1 Asia-Pacific Cardiometabolic Drug Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Cardiometabolic Drug Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Cardiometabolic Drug Market Size (2016-2027)
9.2 Latin America Cardiometabolic Drug Market Size by Type
9.2.1 Latin America Cardiometabolic Drug Market Size by Type (2016-2021)
9.2.2 Latin America Cardiometabolic Drug Market Size by Type (2022-2027)
9.2.3 Latin America Cardiometabolic Drug Market Size by Type (2016-2027)
9.3 Latin America Cardiometabolic Drug Market Size by Application
9.3.1 Latin America Cardiometabolic Drug Market Size by Application (2016-2021)
9.3.2 Latin America Cardiometabolic Drug Market Size by Application (2022-2027)
9.3.3 Latin America Cardiometabolic Drug Market Size by Application (2016-2027)
9.4 Latin America Cardiometabolic Drug Market Size by Country
9.4.1 Latin America Cardiometabolic Drug Market Size by Country (2016-2021)
9.4.2 Latin America Cardiometabolic Drug Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Cardiometabolic Drug Market Size (2016-2027)
10.2 Middle East & Africa Cardiometabolic Drug Market Size by Type
10.2.1 Middle East & Africa Cardiometabolic Drug Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Cardiometabolic Drug Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Cardiometabolic Drug Market Size by Type (2016-2027)
10.3 Middle East & Africa Cardiometabolic Drug Market Size by Application
10.3.1 Middle East & Africa Cardiometabolic Drug Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Cardiometabolic Drug Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Cardiometabolic Drug Market Size by Application (2016-2027)
10.4 Middle East & Africa Cardiometabolic Drug Market Size by Country
10.4.1 Middle East & Africa Cardiometabolic Drug Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Cardiometabolic Drug Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Gilead Sciences
11.1.1 Gilead Sciences Company Details
11.1.2 Gilead Sciences Business Overview
11.1.3 Gilead Sciences Cardiometabolic Drug Introduction
11.1.4 Gilead Sciences Revenue in Cardiometabolic Drug Business (2016-2021)
11.1.5 Gilead Sciences Recent Development
11.2 AbbVie
11.2.1 AbbVie Company Details
11.2.2 AbbVie Business Overview
11.2.3 AbbVie Cardiometabolic Drug Introduction
11.2.4 AbbVie Revenue in Cardiometabolic Drug Business (2016-2021)
11.2.5 AbbVie Recent Development
11.3 Sanofi
11.3.1 Sanofi Company Details
11.3.2 Sanofi Business Overview
11.3.3 Sanofi Cardiometabolic Drug Introduction
11.3.4 Sanofi Revenue in Cardiometabolic Drug Business (2016-2021)
11.3.5 Sanofi Recent Development
11.4 InovoBiologic
11.4.1 InovoBiologic Company Details
11.4.2 InovoBiologic Business Overview
11.4.3 InovoBiologic Cardiometabolic Drug Introduction
11.4.4 InovoBiologic Revenue in Cardiometabolic Drug Business (2016-2021)
11.4.5 InovoBiologic Recent Development
11.5 Carmel Biosciences
11.5.1 Carmel Biosciences Company Details
11.5.2 Carmel Biosciences Business Overview
11.5.3 Carmel Biosciences Cardiometabolic Drug Introduction
11.5.4 Carmel Biosciences Revenue in Cardiometabolic Drug Business (2016-2021)
11.5.5 Carmel Biosciences Recent Development
11.6 Genfit
11.6.1 Genfit Company Details
11.6.2 Genfit Business Overview
11.6.3 Genfit Cardiometabolic Drug Introduction
11.6.4 Genfit Revenue in Cardiometabolic Drug Business (2016-2021)
11.6.5 Genfit Recent Development
11.7 Kochi Prefecture
11.7.1 Kochi Prefecture Company Details
11.7.2 Kochi Prefecture Business Overview
11.7.3 Kochi Prefecture Cardiometabolic Drug Introduction
11.7.4 Kochi Prefecture Revenue in Cardiometabolic Drug Business (2016-2021)
11.7.5 Kochi Prefecture Recent Development
11.8 Besins Healthcare
11.8.1 Besins Healthcare Company Details
11.8.2 Besins Healthcare Business Overview
11.8.3 Besins Healthcare Cardiometabolic Drug Introduction
11.8.4 Besins Healthcare Revenue in Cardiometabolic Drug Business (2016-2021)
11.8.5 Besins Healthcare Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Cardiometabolic Drug Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Impaired Glucose Tolerance Drug
Table 3. Key Players of Insulin Resistance Drug
Table 4. Key Players of Hypertension Drug
Table 5. Key Players of Dyslipidemia Drug
Table 6. Key Players of Central Adiposity Drug
Table 7. Global Cardiometabolic Drug Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Cardiometabolic Drug Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Cardiometabolic Drug Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Cardiometabolic Drug Market Share by Regions (2016-2021)
Table 11. Global Cardiometabolic Drug Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Cardiometabolic Drug Market Share by Regions (2022-2027)
Table 13. Cardiometabolic Drug Market Trends
Table 14. Cardiometabolic Drug Market Drivers
Table 15. Cardiometabolic Drug Market Challenges
Table 16. Cardiometabolic Drug Market Restraints
Table 17. Global Cardiometabolic Drug Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Cardiometabolic Drug Market Share by Players (2016-2021)
Table 19. Global Top Cardiometabolic Drug Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Cardiometabolic Drug as of 2020)
Table 20. Ranking of Global Top Cardiometabolic Drug Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Cardiometabolic Drug Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Cardiometabolic Drug Product Solution and Service
Table 24. Date of Enter into Cardiometabolic Drug Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Cardiometabolic Drug Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Cardiometabolic Drug Revenue Market Share by Type (2016-2021)
Table 28. Global Cardiometabolic Drug Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Cardiometabolic Drug Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Cardiometabolic Drug Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Cardiometabolic Drug Revenue Market Share by Application (2016-2021)
Table 32. Global Cardiometabolic Drug Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Cardiometabolic Drug Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Cardiometabolic Drug Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Cardiometabolic Drug Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Cardiometabolic Drug Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Cardiometabolic Drug Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Cardiometabolic Drug Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Cardiometabolic Drug Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Cardiometabolic Drug Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Cardiometabolic Drug Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Cardiometabolic Drug Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Cardiometabolic Drug Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Cardiometabolic Drug Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Cardiometabolic Drug Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Cardiometabolic Drug Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Cardiometabolic Drug Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Cardiometabolic Drug Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Cardiometabolic Drug Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Cardiometabolic Drug Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Cardiometabolic Drug Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Cardiometabolic Drug Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Cardiometabolic Drug Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Cardiometabolic Drug Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Cardiometabolic Drug Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Cardiometabolic Drug Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Cardiometabolic Drug Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Cardiometabolic Drug Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Cardiometabolic Drug Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Cardiometabolic Drug Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Cardiometabolic Drug Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Cardiometabolic Drug Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Cardiometabolic Drug Market Size by Country (2022-2027) & (US$ Million)
Table 64. Gilead Sciences Company Details
Table 65. Gilead Sciences Business Overview
Table 66. Gilead Sciences Cardiometabolic Drug Product
Table 67. Gilead Sciences Revenue in Cardiometabolic Drug Business (2016-2021) & (US$ Million)
Table 68. Gilead Sciences Recent Development
Table 69. AbbVie Company Details
Table 70. AbbVie Business Overview
Table 71. AbbVie Cardiometabolic Drug Product
Table 72. AbbVie Revenue in Cardiometabolic Drug Business (2016-2021) & (US$ Million)
Table 73. AbbVie Recent Development
Table 74. Sanofi Company Details
Table 75. Sanofi Business Overview
Table 76. Sanofi Cardiometabolic Drug Product
Table 77. Sanofi Revenue in Cardiometabolic Drug Business (2016-2021) & (US$ Million)
Table 78. Sanofi Recent Development
Table 79. InovoBiologic Company Details
Table 80. InovoBiologic Business Overview
Table 81. InovoBiologic Cardiometabolic Drug Product
Table 82. InovoBiologic Revenue in Cardiometabolic Drug Business (2016-2021) & (US$ Million)
Table 83. InovoBiologic Recent Development
Table 84. Carmel Biosciences Company Details
Table 85. Carmel Biosciences Business Overview
Table 86. Carmel Biosciences Cardiometabolic Drug Product
Table 87. Carmel Biosciences Revenue in Cardiometabolic Drug Business (2016-2021) & (US$ Million)
Table 88. Carmel Biosciences Recent Development
Table 89. Genfit Company Details
Table 90. Genfit Business Overview
Table 91. Genfit Cardiometabolic Drug Product
Table 92. Genfit Revenue in Cardiometabolic Drug Business (2016-2021) & (US$ Million)
Table 93. Genfit Recent Development
Table 94. Kochi Prefecture Company Details
Table 95. Kochi Prefecture Business Overview
Table 96. Kochi Prefecture Cardiometabolic Drug Product
Table 97. Kochi Prefecture Revenue in Cardiometabolic Drug Business (2016-2021) & (US$ Million)
Table 98. Kochi Prefecture Recent Development
Table 99. Besins Healthcare Company Details
Table 100. Besins Healthcare Business Overview
Table 101. Besins Healthcare Revenue in Cardiometabolic Drug Business (2016-2021) & (US$ Million)
Table 102. Besins Healthcare Recent Development
Table 103. Research Programs/Design for This Report
Table 104. Key Data Information from Secondary Sources
Table 105. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Cardiometabolic Drug Market Share by Type: 2020 VS 2027
Figure 2. Impaired Glucose Tolerance Drug Features
Figure 3. Insulin Resistance Drug Features
Figure 4. Hypertension Drug Features
Figure 5. Dyslipidemia Drug Features
Figure 6. Central Adiposity Drug Features
Figure 7. Global Cardiometabolic Drug Market Share by Application: 2020 VS 2027
Figure 8. Hospital Pharmacies Case Studies
Figure 9. Online Pharnacies Case Studies
Figure 10. Retail Pharmacies Case Studies
Figure 11. Cardiometabolic Drug Report Years Considered
Figure 12. Global Cardiometabolic Drug Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Cardiometabolic Drug Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Cardiometabolic Drug Market Share by Regions: 2020 VS 2027
Figure 15. Global Cardiometabolic Drug Market Share by Regions (2022-2027)
Figure 16. Global Cardiometabolic Drug Market Share by Players in 2020
Figure 17. Global Top Cardiometabolic Drug Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Cardiometabolic Drug as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Cardiometabolic Drug Revenue in 2020
Figure 19. Global Cardiometabolic Drug Revenue Market Share by Type (2016-2021)
Figure 20. Global Cardiometabolic Drug Revenue Market Share by Type (2022-2027)
Figure 21. North America Cardiometabolic Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Cardiometabolic Drug Market Share by Type (2016-2027)
Figure 23. North America Cardiometabolic Drug Market Share by Application (2016-2027)
Figure 24. North America Cardiometabolic Drug Market Share by Country (2016-2027)
Figure 25. United States Cardiometabolic Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Cardiometabolic Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Cardiometabolic Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Cardiometabolic Drug Market Share by Type (2016-2027)
Figure 29. Europe Cardiometabolic Drug Market Share by Application (2016-2027)
Figure 30. Europe Cardiometabolic Drug Market Share by Country (2016-2027)
Figure 31. Germany Cardiometabolic Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Cardiometabolic Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Cardiometabolic Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Cardiometabolic Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Cardiometabolic Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Cardiometabolic Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Cardiometabolic Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Cardiometabolic Drug Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Cardiometabolic Drug Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Cardiometabolic Drug Market Share by Region (2016-2027)
Figure 41. China Cardiometabolic Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Cardiometabolic Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Cardiometabolic Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Cardiometabolic Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Cardiometabolic Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Cardiometabolic Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Cardiometabolic Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Cardiometabolic Drug Market Share by Type (2016-2027)
Figure 49. Latin America Cardiometabolic Drug Market Share by Application (2016-2027)
Figure 50. Latin America Cardiometabolic Drug Market Share by Country (2016-2027)
Figure 51. Mexico Cardiometabolic Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Cardiometabolic Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Cardiometabolic Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Cardiometabolic Drug Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Cardiometabolic Drug Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Cardiometabolic Drug Market Share by Country (2016-2027)
Figure 57. Turkey Cardiometabolic Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Cardiometabolic Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Cardiometabolic Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Gilead Sciences Revenue Growth Rate in Cardiometabolic Drug Business (2016-2021)
Figure 61. AbbVie Revenue Growth Rate in Cardiometabolic Drug Business (2016-2021)
Figure 62. Sanofi Revenue Growth Rate in Cardiometabolic Drug Business (2016-2021)
Figure 63. InovoBiologic Revenue Growth Rate in Cardiometabolic Drug Business (2016-2021)
Figure 64. Carmel Biosciences Revenue Growth Rate in Cardiometabolic Drug Business (2016-2021)
Figure 65. Genfit Revenue Growth Rate in Cardiometabolic Drug Business (2016-2021)
Figure 66. Kochi Prefecture Revenue Growth Rate in Cardiometabolic Drug Business (2016-2021)
Figure 67. Besins Healthcare Revenue Growth Rate in Cardiometabolic Drug Business (2016-2021)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed

---